A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol
Crossref DOI link: https://doi.org/10.1186/s12885-015-1072-9
Published Online: 2015-02-21
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Kümler, Iben
Balslev, Eva
Stenvang, Jan
Brünner, Nils
Nielsen, Dorte
License valid from 2015-02-21